Glecaprevir/pibrentasvir was effective in both treatment-naive and treatment-experienced patients with no treatment-related serious adverse events or discontinuations due to adverse events.
The SVR12 rate for 8 weeks of glecaprevir/pibrentasvir was noninferior to 12 weeks, which was noninferior to the rate achieved with standard-of-care sofosbuvir plus daclatasvir for 12 weeks.
Ribavirin-free regimen noninferior to current standard-of-care DAA regimens and well tolerated in this challenging-to-treat patient population.
12-weeks of NGM282 resulted in normalization of liver fat content and serum ALT levels in one third of treated patients, as well as improvements in other key biomarkers of NASH and fibrosis.
Higher rates of ALT normalization and improved bone and renal safety markers with TAF vs TDF.
Predictors of delisting include MELD score at the start of DAA therapy and the magnitude of change in MELD score after 12 weeks of treatment.
Biomarker and histologic improvements were greater following treatment with selonsertib as compared with treatment with the humanized monoclonal antibody simtuzumab, which is designed to treat fibrosis.
Treatment with velpatasvir/sofosbuvir regimens yielded 100% SVR rates, whereas daclatasvir plus sofosbuvir regimens yielded 92% to 100% SVR rates.
100% SVR12 rates observed in patients who previously failed NS3/4A PI regimens; lowest SVR12 rates of 79% to 81% observed in patients who failed both NS3/4A PI and NS5A inhibitor regimens.
Novel fixed-dose combination regimen effective in both cirrhotic and noncirrhotic patients with no serious drug-related adverse events or toxicity-driven discontinuations.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.